The Mediterranean diet represents the most well-documented dietary approach to complement tirzepatide treatment. Rich in anti-inflammatory foods and low in ultra-processed products, it optimizes the metabolic results of the treatment. Why the Mediterranean diet is ideal with tirzepatide The Mediterranean diet has been recognized by the WHO and the World Obesity Federation as the … Read more
Gastroparesis is a rare but potentially debilitating side effect of GLP-1 agonists. Here’s how to recognize and prevent it. Gastroparesis, defined by an abnormal slowing of gastric emptying without mechanical obstruction, has received considerable media attention with the rise of GLP-1 treatments. Although rare, this complication can be debilitating and … Read more
Hair loss with GLP-1 agonists is a concern for patients. Here’s what science really says about this phenomenon. Hair loss (alopecia) is a growing concern among patients on GLP-1 agonists, amplified by testimonials on social media. But what do scientific data really say? Is it a … Read more
The SUMMIT study demonstrates that tirzepatide significantly improves symptoms and prognosis of heart failure in obese patients. Heart failure with preserved ejection fraction (HFpEF) is one of the most frequent and challenging forms of heart failure to treat, particularly affecting obese patients. The SUMMIT study, published in the New England … Read more
The SURMOUNT-Jr study paves the way for the treatment of severe obesity in adolescents with tirzepatide, showing superior results to any existing treatment. Pediatric obesity is a global public health crisis. In France, approximately 18% of children and adolescents are overweight or obese, with major physical and psychological consequences. The SURMOUNT-Jr study, … Read more
Discontinuing tirzepatide leads to weight regain in the majority of patients. Here are the scientific data and strategies to limit this phenomenon. One of the most important questions for patients on Mounjaro is: what happens when treatment is stopped? Data from the SURMOUNT-4 study and observational studies provide … Read more
Tirzepatide could become the first effective drug treatment for non-alcoholic steatohepatitis (NASH), a disease affecting millions of French people. Non-alcoholic fatty liver disease (NAFLD), and its progressive form, steatohepatitis (NASH), represent one of the greatest silent epidemics of the 21st century. In France, it is estimated that 18 to 25% of … Read more
The SURMOUNT-OSA study demonstrates that tirzepatide significantly reduces the severity of obstructive sleep apnea, offering an alternative to mechanical treatments. Obstructive sleep apnea (OSA) affects approximately 30 to 40% of obese individuals. This condition, characterized by repeated interruptions of breathing during sleep, increases cardiovascular risk and significantly deteriorates … Read more
With tirzepatide, weight loss isn’t just fat. Understanding body composition is essential to optimize your treatment. One of the major concerns during rapid weight loss is the loss of muscle mass. With GLP-1 agonists like tirzepatide, this issue is even more relevant as weight loss … Read more
How much weight can one truly lose with Mounjaro? A synthesis of all clinical data available in 2026. The most frequent question from patients considering Mounjaro treatment is simple: how much will I lose? The answer, based on data from 8 major clinical trials involving over 20,000 … Read more
The SURPASS-CVOT study is the largest cardiovascular trial ever conducted with tirzepatide. Its results could transform treatment recommendations. The question of cardiovascular safety for anti-obesity treatments is fundamental. The SURPASS-CVOT (Cardiovascular Outcomes Trial) study was designed to evaluate whether tirzepatide (Mounjaro) reduces the risk of major cardiovascular events in patients … Read more
The SURMOUNT-3 and SURMOUNT-4 studies answer the crucial question: what happens long-term with tirzepatide? One of the main challenges of anti-obesity treatments is long-term weight loss maintenance. The SURMOUNT-3 and SURMOUNT-4 studies, published in 2023 and 2024, provide essential data on the durability … Read more